“The inspection of the facility closed with issuance of a Form-483 with eight observations each for the drug product facility and active pharmaceutical ingredient (API) facility at the site,” it added.
The company is committed to addressing the observations and will work with the US health regulator to resolve the issues at the earliest, Lupin said.
On October 30, the drug maker announced that the US health regulator has issued Form-483 with five observations following a pre-approval inspection of its Unit-2 injectable manufacturing facility at Nagpur.
Shares of Lupin closed 0.11 per cent down at Rs 718 apiece on the BSE.
(With inputs from health)